This week, researchers revealed exciting results from the GCIG INTERLACE clinical trial, showing that a new way of using existing cancer drugs could mean more effective treatment options for cervical cancer.
Blog
Posted by Katie Musialowski, Senior Information Officer, 4:15 pm
Categories: Research | advanced cervical cancer | cervical cancer | treatment | support | Katie Musialowski, Senior Information Officer
Posted by Eluned Hughes, Head of Information and Engagement, 2:15 pm
Today the Scottish Medicines Consortium (SMC) has approved the use of a new drug, pembrolizumab (Keytruda), on the NHS to treat some patients with advanced cervical cancer.